Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Otsuka and Galenea extend schizophrenia research

Otsuka and Galenea extend schizophrenia research

7th October 2008

Otsuka Pharmaceutical and Galnea have announced an extension and expansion of their research and development partnership.

The firms have been collaborating since January 2005 on the discovery and development of novel medications for central nervous system (CNS) diseases including schizophrenia.

Under the revised terms of the deal, their initial five-year alliance will be extended for a further year, and the total amount committed to funding for the partnership has been increased to over $75 million (43 million pounds).

It has been reported Gaelnea has made a number of advances in several projects within the partnership, including the development of molecules to lead optimisation stage, with each representing a potential drug candidate with its own mechanism of action.

Taro Iwamoto, president and representative director of Otsuka Pharmaceutical, said: “We are enthusiastic about the continuation of this collaboration with Galenea and see good prospects for the selection of several development candidates in the near term.”

He added there a number of CNS diseases that are not yet properly defined, though therapies for these conditions have shown marked progress in recent years.

In August 2008, Otsuka Pharmaceutical announced a capital investment to purchase Czech firm Interpharma Praha.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.